BG105162A - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
BG105162A
BG105162A BG105162A BG10516201A BG105162A BG 105162 A BG105162 A BG 105162A BG 105162 A BG105162 A BG 105162A BG 10516201 A BG10516201 A BG 10516201A BG 105162 A BG105162 A BG 105162A
Authority
BG
Bulgaria
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
BG105162A
Other languages
Bulgarian (bg)
English (en)
Inventor
Thomas BOCAN
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of BG105162A publication Critical patent/BG105162A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BG105162A 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions BG105162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
BG105162A true BG105162A (en) 2001-12-29

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105162A BG105162A (en) 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (ja)
JP (1) JP2002521328A (ja)
KR (1) KR20010083134A (ja)
CN (1) CN1310629A (ja)
AP (1) AP2001002035A0 (ja)
AU (1) AU4701799A (ja)
BG (1) BG105162A (ja)
BR (1) BR9912296A (ja)
CA (1) CA2335062A1 (ja)
CZ (1) CZ2001126A3 (ja)
EA (1) EA200100153A1 (ja)
EE (1) EE200100046A (ja)
HR (1) HRP20010055A2 (ja)
HU (1) HUP0102880A3 (ja)
ID (1) ID30030A (ja)
IL (1) IL140982A0 (ja)
IS (1) IS5809A (ja)
NO (1) NO20010291D0 (ja)
OA (1) OA11584A (ja)
PL (1) PL346011A1 (ja)
SK (1) SK502001A3 (ja)
TR (1) TR200100205T2 (ja)
WO (1) WO2000004892A2 (ja)
YU (1) YU3501A (ja)
ZA (1) ZA200100294B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2382676A1 (en) * 1999-11-05 2001-05-17 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
AU8254101A (en) * 2000-09-01 2002-03-22 Sankyo Co Medicinal compositions
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
JP4606027B2 (ja) * 2002-04-03 2011-01-05 トポターゲット ユーケー リミテッド Ｈｄａｃ阻害剤としてのピペラジン結合を有するカルバミン酸化合物
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
EP3244883A1 (en) * 2015-01-15 2017-11-22 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
PT841913E (pt) * 1995-08-04 2003-06-30 Warner Lambert Co Utilizacao de derivados sulfamico acil sulfonamidas ou sulfonil carbamatos para a producao de um medicamento para reduzir os niveis de lipoproteinas
CA2253342A1 (en) * 1996-05-17 1997-11-27 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
KR20000068414A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도

Also Published As

Publication number Publication date
EE200100046A (et) 2002-06-17
HUP0102880A3 (en) 2002-11-28
TR200100205T2 (tr) 2001-05-21
IS5809A (is) 2001-01-12
WO2000004892A3 (en) 2000-05-18
ID30030A (id) 2001-11-01
NO20010291L (no) 2001-01-18
CA2335062A1 (en) 2000-02-03
EA200100153A1 (ru) 2001-08-27
SK502001A3 (en) 2002-06-04
BR9912296A (pt) 2001-04-17
WO2000004892A2 (en) 2000-02-03
HUP0102880A2 (en) 2002-06-29
CN1310629A (zh) 2001-08-29
NO20010291D0 (no) 2001-01-18
YU3501A (sh) 2005-06-10
ZA200100294B (en) 2002-01-10
AU4701799A (en) 2000-02-14
OA11584A (en) 2004-07-20
HRP20010055A2 (en) 2002-04-30
JP2002521328A (ja) 2002-07-16
PL346011A1 (en) 2002-01-14
CZ2001126A3 (cs) 2002-01-16
EP1098662A2 (en) 2001-05-16
IL140982A0 (en) 2002-02-10
KR20010083134A (ko) 2001-08-31
AP2001002035A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
BG105162A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
EP1100392A4 (en) METHODS AND DEVICES FOR REDUCING THE MINERAL CONTENT OF VASCULAR CALCIFIED LESIONS
EP1935423A3 (de) Zusammensetzung zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
BG105369A (en) Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp
CY1109636T1 (el) Συνθεση στοματικης δοσης παρατεταμενης απελευθερωσης
IL128080A0 (en) Thiol sulfonamide metalloprotease inhibitors
IL141957A0 (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
GB9804886D0 (en) Therapeutic combination
EP0964686A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING THE DEVELOPMENT OF ATHEROSCLERIC LESIONS
HUP0103424A3 (en) Use of eletriptan for the prevention of migraine recurrence
FR2744621B1 (fr) Determination des tunnels femoral et tibial pour la reconstruction isometrique du ligament croise anterieur
AU2002230390A1 (en) Ixodes scapularis tissue factor pathway inhibitor
EP0755679A3 (en) Use of Amtolmetin Guacil as an anti-inflammatory agent, which also inhibits gastric secretion
IT1302813B1 (it) Dispositivo per la riduzione diretta di ossidi di ferroe relativo procedimento
AU4144099A (en) Use of an agent for the prevention of gum disease
GB9824875D0 (en) Use of an agent for the prevention of gum disease
MXPA02011810A (es) Utilizacion del riluzol o sus sales para la prevencion y el tratamiento de la adrenoleucodistrofia.
EP1115687A4 (en) 5,6-DIHYDRONAPHTHALENYL DERIVATIVES WITH RETINOID-LIKE ACTIVITY
KR960027392U (ko) 로터리 압축기의 마모감소장치
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence
IT1321047B1 (it) Procedimento e dispositivo per il rilevamento dell'avvenutadisattvazione di un dispositivo di frenatura, particolarmente per un
KR960014949U (ko) 브레이크 라이닝의 마모감지장치
ZA97168B (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of prostatic carcinoma